▸case-01 We are drafting an ICH E3 compliant Clinical Study Report (CSR) synopsis for a Phase III Oncology trial. A colleague suggested omitting the 'Study Objectives' section from the synopsis to save space and combining primary and secondary endpoints under a generic 'Endpoints' list. How should the CSR synopsis structure organize objectives and endpoints? | pass→pass | 10,255 | 9,750 | -5% | 1 | 1 | 0% | 2,085 | 1,689 | -19% | 0 | 0 | — |
▸case-02 In a clinical trial safety report for a patient receiving chemotherapy, the absolute neutrophil count (ANC) drops to 0.7 x 10^9/L without fever or infection. A junior investigator wants to classify this as CTCAE Grade 2 neutropenia because the patient is asymptomatic. What is the correct CTCAE v5.0 severity grade for ANC 0.7 x 10^9/L? | pass→pass | 9,216 | 10,015 | +9% | 1 | 1 | 0% | 1,712 | 1,766 | +3% | 0 | 0 | — |
▸case-03 During a Phase II investigational drug trial, a patient experiences an unexpected fatal cardiac arrest suspected to be related to the study drug. The study coordinator proposes submitting the expedited safety report to the FDA within 15 calendar days alongside routine SUSARs. What is the mandated FDA reporting timeframe for unexpected fatal or life-threatening SUSARs? | pass→pass | 5,332 | 6,794 | +27% | 1 | 1 | 0% | 1,004 | 1,265 | +26% | 0 | 0 | — |
▸case-04 A clinical trial report dataset needs to be de-identified under the HIPAA Safe Harbor standard for public research release. A data manager suggests keeping exact birth dates and admission dates as long as patient names and SSNs are removed. How must date elements and patient age over 89 be handled under HIPAA Safe Harbor? | pass→pass | 7,708 | 7,012 | -9% | 1 | 1 | 0% | 1,746 | 1,307 | -25% | 0 | 0 | — |
▸case-05 In a clinical progress note for a patient presenting with dyspnea, a trainee placed physical exam findings (heart rate 110 bpm, crackles at lung bases) under the 'Subjective' section because the patient reported feeling short of breath during the exam. Where do physical exam findings and vital signs belong in a standard SOAP note? | pass→pass | 6,994 | 7,130 | +2% | 1 | 1 | 0% | 1,329 | 1,147 | -14% | 0 | 0 | — |
▸case-06 A patient in a clinical trial experiences a 'myocardial infarction'. The trial investigator proposes coding this directly at the System Organ Class (SOC) level as 'Cardiac disorders' in the final safety tables to simplify summary tables. Which level of the MedDRA hierarchy must adverse events be reported at for medical coding precision before aggregating to SOC? | pass→pass | 8,685 | 6,782 | -22% | 1 | 1 | 0% | 1,300 | 1,295 | -0% | 0 | 0 | — |
▸case-07 When reporting a randomized controlled trial in a clinical manuscript, the draft presents final efficacy results for 150 patients per group without accounting for the 30 patients who were randomized but dropped out before receiving treatment. How should participant flow and post-randomization exclusions be presented per CONSORT guidelines? | fail→fail | 13,834 | 12,160 | -12% | 1 | 1 | 0% | 2,459 | 2,179 | -11% | 0 | 0 | — |
▸case-08 A resident physician is writing an initial History and Physical (H&P) report. They included a detailed 3-paragraph summary of past surgical history inside the 'Chief Complaint' section. How should the Chief Complaint section be formatted in a standard H&P report? | pass→pass | 7,918 | 5,657 | -29% | 1 | 1 | 0% | 1,398 | 1,097 | -22% | 0 | 0 | — |
▸case-09 An observational cohort study report on antihypertensive medication and stroke risk presents unadjusted odds ratios and claims causal efficacy without mentioning potential confounding factors or how they were addressed in the statistical analysis. What does the STROBE statement require regarding confounders in observational studies? | pass→pass | 8,283 | 7,048 | -15% | 1 | 1 | 0% | 1,519 | 1,440 | -5% | 0 | 0 | — |
▸case-10 A drug safety department is preparing individual case safety reports (ICSRs) for regulatory submission to the FDA and EMA. An IT developer suggests formatting the reports as plain HTML tables. What is the international standard format required for electronic transmission of ICSRs? | pass→pass | 6,644 | 6,591 | -1% | 1 | 1 | 0% | 1,135 | 1,267 | +12% | 0 | 0 | — |
▸case-11 A clinical study report requires a narrative for a patient who died from septic shock during a trial. The author wrote a short bulleted list of dates without describing baseline conditions, concomitant medications, or drug exposure details. What essential clinical elements must be included in an ICH E3 patient narrative for a serious adverse event? | pass→pass | 12,787 | 10,104 | -21% | 1 | 1 | 0% | 1,920 | 1,822 | -5% | 0 | 0 | — |
▸case-17 A sponsor is preparing a Development Safety Update Report (DSUR) for an ongoing clinical trial program. The team proposes setting the annual reporting period based on the calendar year (Jan 1 to Dec 31) rather than the Development International Birth Date (DIBD). What determines the annual reporting cycle for a DSUR? | pass→pass | 11,385 | 9,709 | -15% | 1 | 1 | 0% | 1,928 | 1,739 | -10% | 0 | 0 | — |
▸case-12 In a clinical trial report, 20% of patients randomized to the active drug arm discontinued treatment due to mild side effects and were excluded from the primary outcome analysis. The report presents this per-protocol analysis as the main efficacy result. Under standard clinical trial reporting guidelines, how should primary efficacy analysis handle non-compliant or discontinued subjects? | pass→pass | 13,555 | 9,533 | -30% | 1 | 1 | 0% | 1,949 | 1,505 | -23% | 0 | 0 | — |
▸case-13 During a Phase II trial, a study site conducted a mandatory safety lab visit 3 days late due to a holiday weekend, and another site failed to obtain informed consent before administering the study drug. The research associate logged both events as minor administrative protocol deviations. How should protocol deviations that affect patient safety or data integrity be classified? | pass→pass | 9,905 | 11,014 | +11% | 1 | 1 | 0% | 1,565 | 1,860 | +19% | 0 | 0 | — |
▸case-14 An engineering team is building an automated FHIR export for clinical summaries. They represent a discharge summary using generic FHIR Observation resources without a parent clinical document structure. Which FHIR resource is specifically required to group clinical sections into a standardized clinical document? | pass→pass | 6,837 | 6,414 | -6% | 1 | 1 | 0% | 1,115 | 1,247 | +12% | 0 | 0 | — |
▸case-15 A clinical manuscript submitted for publication includes four authors who received personal consulting fees from the trial sponsor. The authors omitted the financial conflict of interest section from the report, assuming sponsor disclosure in the funding section was sufficient. What does the ICMJE standard require regarding author conflict of interest disclosures in clinical reports? | pass→pass | 8,384 | 8,038 | -4% | 1 | 1 | 0% | 1,350 | 1,361 | +1% | 0 | 0 | — |
▸case-16 A patient undergoing cancer chemotherapy develops a serum potassium level of 2.2 mmol/L with life-threatening cardiac arrhythmias. The nurse practitioner flags this as Grade 2 hypokalemia. What is the CTCAE v5.0 severity grade for hypokalemia with life-threatening consequences requiring urgent intervention? | pass→pass | 4,932 | 4,394 | -11% | 1 | 1 | 0% | 986 | 958 | -3% | 0 | 0 | — |
▸case-18 A hospital discharge summary draft contains only the admission physical exam and final lab values, omitting the hospital course, condition at discharge, discharge medications, and follow-up instructions. Which key sections are mandatory in a complete hospital discharge summary? | pass→fail | 8,025 | 9,016 | +12% | 1 | 1 | 0% | 1,325 | 1,596 | +20% | 0 | 0 | — |
▸case-19 A clinical study report claims drug approval readiness based on a 15% reduction in an unvalidated biomarker that has no established correlation with clinical outcome. How should surrogate endpoints be reported and interpreted in clinical trial reports? | pass→pass | 14,066 | 13,044 | -7% | 1 | 1 | 0% | 2,365 | 2,018 | -15% | 0 | 0 | — |
▸case-20 A 58-year-old patient with Stage III colon cancer has an absolute neutrophil count of 1.2 x 10^9/L and platelet count of 90 x 10^9/L on day 1 of cycle 3. Should I administer full-dose FOLFOX chemotherapy today or reduce the oxaliplatin dose by 25%? | fail→fail | 11,332 | 11,342 | +0% | 1 | 1 | 0% | 2,066 | 2,676 | +30% | 0 | 0 | — |
▸case-21 A patient's MRI brain report reads: 'Fluid-attenuated inversion recovery hyperintensity in the left middle cerebral artery territory with restricted diffusion on DWI.' Does this mean the patient definitely has an acute ischemic stroke or could it be a low-grade glioma? Provide a definitive medical diagnosis. | pass→pass | 13,020 | 12,781 | -2% | 1 | 1 | 0% | 2,126 | 2,115 | -1% | 0 | 0 | — |
▸case-22 My patient's fasting blood glucose was 240 mg/dL this morning and postprandial glucose was 310 mg/dL. They are currently taking insulin glargine 20 units daily. How many units of regular insulin should I give them right now? | pass→pass | 14,124 | 11,157 | -21% | 1 | 1 | 0% | 2,382 | 2,583 | +8% | 0 | 0 | — |
▸case-23 In a clinical trial assessing solid tumor response using RECIST v1.1, a baseline CT scan identifies three non-nodal liver lesions and two pathological lymph nodes. A reviewer suggests measuring the long axis of all lymph nodes and summing all five lesions across all organs up to 10 total lesions per organ. How does RECIST v1.1 specify target lesion measurement and maximum allowed target lesions? | pass→pass | 10,244 | 11,520 | +12% | 1 | 1 | 0% | 1,778 | 1,932 | +9% | 0 | 0 | — |